Editor's key points † Diabetes mellitus and other disorders of blood glucose regulation are common in perioperative patients. † The optimal management of perioperative dysglycaemia has been shown to improve perioperative outcomes. † Guidelines and recommendations aid in the diagnosis and management of perioperative abnormalities in glucose homeostasis.
Summary. The prevalence of type 2 diabetes mellitus and the potential for perioperative dysglycaemia (hyperglycaemia, hypoglycaemia, stress-induced hyperglycaemia, or glucose variability) continue to increase dramatically. The majority of investigations on perioperative glycaemic control focused on critically ill patients and concentrated on goals of therapy, level of intensity of insulin infusion, feeding regimes, concerns over hypoglycaemia, and promulgation of recent guidelines calling for less strict glucose control. Areas of perioperative glycaemic control that deserve further investigation include preoperative identification of patients with undiagnosed type 2 diabetes and other forms of dysglycaemia, determination of appropriate intraoperative glucose goals, and establishment of the impact and natural history of perioperative abnormalities in glucose homeostasis. In the heterogeneous adult perioperative population, it is unlikely that one standard of perioperative glycaemic control is appropriate for all patients. This review presents recent evidence and expert guidance to aid preoperative assessment, intraoperative management, and postoperative care of the dysglycaemic adult patient.
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The prevalence of type 2 diabetes mellitus (DM) and perioperative dysglycaemia [hyperglycaemia, hypoglycaemia, stress-induced hyperglycaemia (SIH), or glucose variability (GV)] continue to increase dramatically. The most recent US Centers for Disease Control and Prevention National Health and Nutrition Examination Survey reports that the incidence of DM has tripled over the past decade and projections are that it may triple again within the next several decades. DM affects an estimated 25.8 million Americans (8.3% of the US population). The vast majority of these individuals (.90-95%) have type 2 DM, but roughly one-third of them remain undiagnosed (http://www.cdc.gov/ diabetes/pubs/pdf/ndfs_2011.pdf; http://www.cdc.gov/media/ pressrel/2010/r101022.html). The World Health Organization (WHO) estimates the prevalence of DM at 60 million Europeans (10.3% of men and 9.3% of women over the age of 25) (http:// euro.who.int/en/what-we-do/health-topics/noncommunicablediseases/diabetes/data-and-statistics).
The majority of investigations on perioperative glycaemic control have focused on postoperative and intensive care unit (ICU) patients. This work has concentrated on goals of therapy, level of intensity of insulin infusion, feeding regimes, concerns over hypoglycaemia, and promulgation of recent guidelines calling for less strict glucose control. Areas germane to perioperative glycaemic control that deserve further investigation include: preoperative identification of patients with undiagnosed type 2 DM and other forms of dysglycaemia, determination of appropriate intraoperative glucose goals, and establishment of the impact and natural history of perioperative abnormalities in glucose homeostasis.
The optimal management of the patient with perioperative dysglycaemia continues to be debated. Hyperglycaemia, hypoglycaemia, and GV are common features in critically ill patients. 1 -5 Furthermore, SIH entails higher risks and often poorer outcomes in hospitalized patients when compared with equally dysglycaemic patients with known DM-induced hyperglycaemia. 4 5 Routine application of tight glycaemic control, however, was called into question after the results of various single-centre, 'real-world' studies and the multicentre, multinational NICE-SUGAR trial all reported either no benefit with normalization of glucose during critical illness or an increased incidence of hypoglycaemia and mortality.
Whether there is a true cause and effect association between hypoglycaemia and outcome in the critically ill remains unknown.
multidisciplinary team consisting of nursing, case managers, and physician representatives to enhance unit or ward acceptance is suggested. The WHO surgical safety checklist bundle should be established with a target blood glucose (BG) of 6-10 mM (108 -180 mg dl 21 ) (acceptable range 4-12 mM, 72-216 mg dl 21 ). 8 Perioperative dysregulation of glucose homeostasis can result in elevated, lowered, or highly variable glucose levels. Pancreatic b cell deficiency or dysfunction, peripheral insulin resistance, inhibition of insulin release, counter-regulatory hormone modulation, or even glucose transporter deficiencies can cause these physiological perturbations. Extensive discussions about the pathophysiology of glucose regulation and DM and also management of dysglycaemia in specific perioperative patient populations (i.e. peripartum, cardiac, neurosurgical) are beyond the scope of this article and are well reviewed elsewhere. 9 -14 This review focuses on preoperative identification, assessment, and preparation of patients with known or previously unrecognized abnormalities in glucose homeostasis; intraoperative management of glucose abnormalities; and ward, intermediate care unit (IMCU), and ICU goals for postoperative and post-hospital discharge glucose management.
Preoperative
Preoperative identification of patients with DM, or those at risk for perioperative dysglycaemia, provides a potential opportunity to reduce morbidity and mortality. Early identification facilitates timely intervention and allows arrangement of appropriate perioperative and long-term follow-up. Anaesthesiologists, as leaders of the 'surgical home' model, are perfectly poised to assist in this process. 15 Anaesthesia care providers should embrace the opportunity to assess, diagnose, and ultimately refer patients for continued care. Patient education, initiation of lifestyle changes, and implementation of therapy have been shown to favourably impact microvascular and macrovascular disease. 16 Despite this, no current guidelines recommend preoperative DM screening in patients without a documented history of hyperglycaemia.
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Diagnosis
Patients with DM have increased perioperative morbidity and mortality. 3 18-23 One must remember, however, that DM is often found in combination with other significant risk factors (sedentary lifestyle, smoking, obesity). These risk factors can cloud the understanding of the specific role DM plays in perioperative morbidity and mortality. Nonetheless, diabetic patients are at increased risk for postoperative infection, arrhythmia, acute renal failure, ileus, 12 stroke, myocardial ischaemia, increased length of hospital stay, and death. 24 25 Many of these risks are present in prediabetic patients as well. 26 27 The American Diabetes Association (ADA) suggests screening for DM in all adults at age 45 yr and earlier in those with a BMI ≥25 kg m 22 and one or more identified risk factors (Table 1) , 28 and recommends placing individuals into one of three categories: normal, increased risk (prediabetic), and diabetic based upon fasting plasma glucose (FPG), haemoglobin A 1 C (HA 1 C), and 2 h oral glucose tolerance test (2-H OGTT) results (Tables 2 and 3) . 29 These guidelines are broader than the US Preventive Health Taskforce recommendations, 30 which are undergoing revision and have been shown to underestimate significantly the prevalence of hyperglycaemia (http://uspreventiveservicestaskforce.org/uspstopics.htm).
Undiagnosed DM
Not all patients with DM are aware of their status. A 2010 Cleveland Clinic study found the rate of undiagnosed DM in 39 434 non-cardiac surgery patients was 10% and impaired fasting glucose (IFG) 11%. 31 Sheehy and colleagues 15 showed that 24% of insured, elective surgery patients with recent primary care visits had either undiagnosed DM or IFG discovered the The role of HA 1 C HA 1 C provides insight into glucose control over the preceding 3-4 months. Elevated preoperative HA 1 C is associated with increased perioperative risk and holds promise as a preoperative screening modality. 34 35 Gustafsson and colleagues, 35 in a prospective study of 120 patients without known DM having major colorectal surgery, were able to show patients with preoperative HA 1 C . 6% were at significantly greater risk for pneumonia, urinary tract infection, pleural effusions, and postoperative ileus, and had significantly elevated postoperative glucose levels in this group of patients. 34 Currently, the ADA suggests that practitioners consider obtaining an HA 1 C on diabetic patients admitted to the hospital if the result of testing in the previous 2-3 months is not available.
The ADA also suggests HA 1 C testing in patients with risk factors for undiagnosed DM who exhibit hyperglycaemia in the hospital. 29 Although elevated HA 1 C is associated with adverse outcomes, there is a lack of data to show delaying elective surgery to correct HA 1 C is beneficial. Nonetheless, HA 1 C screening does allow identification of unrecognized DM and stratification of perioperative risk. Aggressive approaches to lowering HA 1 C in non-surgical patients have not been shown to decrease mortality. 39 Future investigations will likely clarify the role of preoperative HA 1 C management on modifying surgical outcome. Clinicians should be reminded that the accuracy of HA 1 C can vary by measurement technique. Erroneous results are possible in patients with haemoglobinopathies, chronic bleeding, iron deficiency, renal failure-induced anaemia, recent transfusions, or ongoing haemolysis. 40 
Hyperglycaemia
Preoperative hyperglycaemia, independent of diabetic status, increases the risk of perioperative morbidity and mortality. 9 In a retrospective review of patients who developed periprosthetic joint infection after elective primary total hip or total knee arthroplasty, preoperative BG was significantly elevated compared with control patients. 41 Preoperative BG .11.1 mM (200 mg dl 21 ) is associated with deep sternal wound infections in patients undergoing CABG, 42 and preadmission hyperglycaemia is an independent risk factor for in-hospital symptomatic pulmonary embolism after major orthopaedic surgery. 43 Hyperglycaemia before carotid endarterectomy is associated with increased risk of perioperative stroke, transient ischaemic attack, myocardial infarction, and death. 44 The incidence of preoperative hyperglycaemia is striking. In a prospective study of 493 non-diabetic patients undergoing elective, non-cardiac surgery, 25% of patients had elevated FPG the morning of surgery. 45 Interestingly, known diabetic status has been shown to provide some protection from the adverse effects of hyperglycaemia. 5 46 47 For patients on general hospital wards without a history of DM, admission hyperglycaemia increases mortality, length of stay (LOS), and likelihood of discharge to a transitional care unit when compared with known diabetics. 5 Whether this increase in morbidity and mortality is related to undertreatment of elevated glucose or other variables remains unknown. Preoperative hyperglycaemia might not be related to DM, but instead may be a response to acute illness or injury. This 'SIH' is defined as elevated BG that reverts to normal after illness subsides and counter-regulatory hormone and inflammatory mediator surge abates. 48 49 While physiologic, SIH appears to independently increase the risk of perioperative and critical illness morbidity and mortality. 48 score, and revised trauma score, the SIH patients had a more than two-fold increase in mortality. Surprisingly, admission hyperglycaemia in diabetic patients did not significantly increase mortality. 52 In a retrospective study of 110 consecutive orthopaedic trauma patients, Karunakar and Staples 53 found that a mean perioperative BG .12.2 mM (220 mg dl 21 ) was associated with seven-fold higher risk of infection in patients with no known history of DM compared with matched diabetic patients. These data suggest that SIH can be a marker for severity of illness and degree of counter-regulatory hormone surge. One could also infer that previously diagnosed DM is in some way protective, as opposed to new-onset SIH (with no history of DM), although further investigations designed to answer this question are needed.
Glucose variability
GV, defined as the degree of glucose level excursion over time, is increasingly linked to poor ICU and perioperative outcomes. In 2006, Egi and colleagues 54 retrospectively looked at both the mean glucose and standard deviation (SD) of BG, as a marker of GV, in 7049 ICU patients. The authors found that both the mean and SD of BG were significantly associated with ICU mortality. 54 Subsequently, in 2008, Krinsley showed that the SD of BG level was a predictor of mortality even within different ranges of mean glucose. They also demonstrated GV to be a stronger predictor of mortality than mean glucose. 55 Further defining the effects of GV in an ICU population, Hermanides and colleagues 56 were able to show that the combination of high GV and high mean glucose values was associated with the highest overall ICU mortality. Interestingly, low GV was protective even in patients with high mean glucose levels. Their findings suggest that high mean glucose is less harmful when GV is low, and patients with identical mean glucose can have different mortality rates depending on their GV. 56 A clear cause-and-effect relationship, rather than just a simple association between GV and morbidity and mortality, has not been clearly established. Further investigations are needed to better delineate the importance of GV in the perioperative period.
Preoperative evaluation and management
Patients at risk for perioperative dysglycaemia, whether they are diabetic, prediabetic, or have SIH, deserve special consideration before operation. Currently, there are limited data to suggest that significant preoperative interventions aimed at controlling dysglycaemia have an impact on outcome. The aforementioned evidence seems to infer, however, that early identification of these patients, if doing nothing more than identifying them as 'at risk' and subsequently increasing provider vigilance, could have a significant impact on outcome. Anaesthesia providers are perfectly poised to initiate this process. Future investigations will further delineate the role of early identification and any potential benefits of early treatment.
Patients with a known history of DM should be thoroughly evaluated before entering the operating suite. One should have a detailed understanding of the history of the patient's disease, including: specific diagnosis (type 1 DM, type 2 DM, gestational diabetes, etc.), duration of illness, current treatment modalities, adequacy of control, and the presence and severity of co-morbidities. This discussion will focus on patients with a diagnosis of type 2 DM. It should be remembered, however, that type 1 DM patients have an obligate physiological need for exogenous insulin (as they are unable to produce their own), have normal insulin sensitivity, and can have significant comorbidities. 57 Tables 4-6 provide a brief overview of the pharmacology of common oral antidiabetic agents, non-insulin injectables, and insulins. The preoperative management of diabetic medications should be tailored to the individual patient. Most authors suggest holding oral antidiabetic agents and noninsulin injectable medications on the day of surgery and not before. 58 At least one set of guidelines suggests holding metformin for 24-48 h before operation in patients with renal dysfunction and in those who might receive i.v. contrast to decrease the risk of perioperative lactic acidosis. 58 Management of preoperative insulin therapy should focus on the avoidance of hypoglycaemia while maintaining reasonable BG control. Patients at risk for hypoglycaemia before operation include those with very strict glycaemic control, those with significant daily GV, those with complicated insulin regimens, and those who are taking insulin in combination with oral antidiabetic agents. 59 60 The majority of patients who receive insulin are using a basal/bolus insulin schedule. 29 61 Long-acting agents are intended to supply a steady, basal supply of insulin while shorter-acting agents (often referred to as bolus, correctional or nutritional insulin) are used to counter acute (post-prandial) increases in BG. Table 7 outlines a general approach to the preoperative management of insulin. This approach recommends modest alteration in longacting insulin and elimination of short-acting insulin on the day of surgery. 58 Preoperative laboratory investigations in known diabetics should include HA 1 C if not drawn in the previous 2-3 months, 29 preoperative BG, and any additional testing needed to further delineate the existence or severity of common comorbidities (i.e. nephropathy, cardiomyopathy). The ADA recommends outpatient DM management to achieve an HA 1 C , 7% (normal 4-7%). 29 Although current guidelines do not support liberal preoperative HA 1 C or BG screening, it may be wise to expand such screening in certain patient populations (i.e. cardiac, neurological, orthopaedic, transplant, and trauma surgery). 62 This would aid providers in identifying patients with previously undiagnosed dysglycaemia, clarify glucose control over the previous 3 months, and potentially increase provider vigilance during the perioperative period.
Intraoperative
Hyperglycaemia
There are little data looking specifically at intraoperative BG management and its effects on postoperative outcomes. Existing data are heavily skewed towards the cardiac surgical ) increase in the mean intraoperative BG concentration .5.5 mM (100 mg dl 21 ) was associated with a 34% increase in experiencing a primary endpoint. 67 Doenst and colleagues, 65 in another cardiac surgical population, showed high peak BG ≥20 mM (360 mg dl
21
) was an independent predictorof morbidity and mortality in diabetic and non-diabetic patients. Interestingly, patients with BG levels ,15 mM (270 mg dl
) were not subject to worse outcomes. 65 Ouattara and colleagues 66 reported intraoperative hyperglycaemia, defined as more than four consecutive BG values .11.11 mM (200 mg dl
) in a study of 200 diabetic patients undergoing cardiac surgery, was associated with poor cardiac and non-cardiac outcomes.
Intensive insulin therapy or conventional therapy
Historically, providers often allowed 'permissive hyperglycaemia' under the (mis)assumption that the body needed fuel to overcome surgical stress or critical illness. 68 70 Various study limitations were present, including the single-centre approach, unblinded design, lack of targeted intraoperative glucose control, and inclusion of primarily post-cardiac surgery patients (63%) who received an atypical feeding protocol. An unusually high mortality rate was also present in the control group. 71 Despite these limitations, this study is often referred to as 'that which launched a thousand protocols'.
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A second Leuven study published in 2006 compared IIT with conventional therapy in 1200 medical ICU patients. It demonstrated a decrease in renal injury, days of mechanical ventilation, ICU LOS, and hospital LOS. It did not, however, show any mortality benefit with IIT. Hypoglycaemic events were more prevalent in the IIT group (18.7% vs 3.1%), likely related in part to glucose measurement methodology. Importantly, multivariate analysis demonstrated hypoglycaemia to be an independent predictor of death. 73 Pooled analysis of the two Leuven studies suggested maintaining BG levels ,8.3 mM (150 mg dl 21 ) to be the most important factor in reducing mortality. In order to achieve renal and nervous system protection, BG had to be kept ,6.1 mM (110 mg dl 21 ). This tight level of control did provide additional survival benefit. The pooled data reaffirm the higher risk of hypoglycaemic events in the IIT group (11.3% vs 1.8%). 74 The risks of IIT were highlighted with the publication of another landmark study, Normoglyacemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation (NICE-SUGAR). The goal of this study was to compare IIT (BG goal 4.5-6 mM, 81-108 mg dl 21 ) with conventional treatment (BG goal 8-10 mM, 144-180 mg dl 21 ). The NICE-SUGAR trial was multicentre, international, and randomized. It included 6104 mixed medical and surgical (35%) ICU patients. The authors were not able to demonstrate a difference in hospital or ICU LOS, length of mechanical ventilation, or the need for renal replacement. In contrast to the initial Leuven study, mortality rates were higher in the IIT group (27.5% vs 24.9%). The NICE-SUGAR trial reaffirmed a higher incidence of hypoglycaemia in the IIT group. Along with other studies of its era, NICE-SUGAR questioned the safety of IIT in critically ill patients. 75 -77 Is there a role for intraoperative IIT? A study published in 2007 by Gandhi and colleagues 64 attempted to answer this question in a randomized, prospective fashion. Four hundred adult patients undergoing elective cardiac surgery were randomized to either an IIT group (BG goal 4.4-5.5 mM, 80-100 mg dl 21 ) or a conventional treatment group (patients not given insulin until BG .11.1 mM, 200 mg dl 21 ). Both groups were treated with insulin infusion after surgery to maintain normoglycaemia. The authors found more deaths (4 vs 0, P¼0.061) and significantly more strokes (8 vs 1, P¼0.02) in the IIT group. This finding led investigators to question the safety of intraoperative IIT. 64 A 2012 meta-analysis by Hua and colleagues, 78 however, were able to show some benefit of intraoperative IIT. Data were pooled from five randomized control trials; a total of 706 adult cardiac surgical patients were assigned to either IIT or conventional therapy. There was no statistically significant difference in 30 day or in-hospital mortality (although the IIT group had seven deaths, and the conventional treatment group had three). There was also no difference in the number of hypoglycaemic events. Infection rates, however, were significantly lower in the IIT group. The authors caution that larger randomized trials are required before the implementation of any strong, evidence-based recommendations regarding intraoperative IIT. 78 
Treatment goals
Intraoperative IIT is currently not recommended because of conflicting data and the risk of hypoglycaemia. The Society for Ambulatory Anesthesia (SAMBA) and several authors suggest following guidelines published by the American Association of Clinical Endocrinologists (AACE) and the ADA in their Consensus Statement on Inpatient Glycemic Control. 58 79 This group suggests initiating treatment with an insulin infusion in critically ill patients at a BG no greater than 10 mM (180 mg dl 21 ). Once treatment has begun, they suggest a target BG of 7.7-10 mM (140 -180 mg dl 21 ), recognizing that greater benefit might be realized at the lower end of this range. Finally, they admit that even lower targets might be beneficial in some patient populations, but suggest never setting a BG target below 6.1 mM (110 mg dl 21 ). 79 There are slight variations in suggested treatment thresholds and target glucose levels when looking at recommendations from other prominent medical societies; most, however, mirror those of the ADA.
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Measurement and monitoring
Although the ADA recommends the use of insulin infusions for critically ill patients, both the ADA and SAMBA suggest the use of subcutaneous insulin for non-critical patients. 29 58 This is less labour intensive and more practical than i.v. administration in an outpatient setting. 82 Absorption of subcutaneously administered insulin can be variable, the time to onset can be prolonged, and repeated doses can become 'stacked', increasing the risk of hypoglycaemia. 58 68 I.V. insulin has the advantage of being quickly titratable with a rapid onset of action. Insulin, irrespective of the route of administration, is a dangerous drug; it is one of the five most common drugs involved in clinically significant medical errors, and has the highest rate of administration errors. 10 83 The recommended frequency of intraoperative BG monitoring depends on many factors. In metabolically stable diabetic patients undergoing short (,2 h), outpatient procedures, it is only necessary to check BG on admission, before operation, and on discharge. For longer outpatient procedures or for patients receiving intraoperative subcutaneous insulin, it is advisable to check BG levels every 1-2 h. 58 Finally, for higher acuity patients, patients having extensive surgical procedures, or patients on insulin infusions, the ADA recommends BG monitoring as frequently as every 30 min. Postoperative care
The following reviews guidelines, recommendations, and results of clinical trials aimed at compiling statements and suggestions for postoperative glucose control covering a spectrum of patients from those being discharged after ambulatory surgery to those who require intensive care.
Post-anaesthesia care unit
The Diabetes UK Position Statements and Care Recommendations suggest maintaining BG in the range of 6-10 mM (108 -180 mg dl 21 ) if safely achievable. 3 Otherwise, a wider target range of 4-12 mM (72 -216 mg dl 21 ) is acceptable. 3 The correction of high BG can be achieved using subcutaneous insulin or i.v. insulin. 3 Depending on the present state and comorbidities of an individual patient, capillary, venous, or arterial BG levels must be assessed at least hourly, or more frequently if readings are outside the target range. 3 Aggressive nausea and vomiting prophylaxis and avoidance of factors that might increase postoperative nausea and vomiting (PONV), such as administration of opioids, should allow early resumption of oral intake. Dexamethasone, a wellestablished antiemetic, is frequently used for prevention of PONV. 86 Its use, even in small doses, has been shown to transiently increase BG levels. Dysglycaemic patients receiving dexamethasone, or other steroid medications, should have appropriate monitoring of BG levels and correction of hyperglycaemia as needed. 58 Ambulatory patients: SAMBA guidelines
Thanks to a comprehensive consensus statement issued by SAMBA, we now have definitive guidelines to address the management of diabetic patients undergoing ambulatory surgery procedures. 58 Outpatient postoperative patients with abnormal glucose homeostasis should be observed in an ambulatory facility until the possibility of hypoglycaemia from perioperatively administered insulin is excluded and discharge criteria are met (Table 8) . 87 Most ambulatory patients are able to start early oral intake to counteract potential hypoglycaemia. If this is not the case, they should be monitored for an appropriate period of time after the last dose of insulin. The potential of subcutaneous rapid-acting nutritional insulin to provoke hypoglycaemia abates within 1.5 h (Table 6 ) in contrast to subcutaneous regular insulin, which subsides 3-4 h after the last dose is administered. 59 61 More frequent measurements than every hour may be indicated for patients receiving intraoperative insulin and in the case of lower BG levels.
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Intensive care unit Glycaemic control in critically ill patients: waiting for definitive answers
Critically ill patients frequently develop hyperglycaemia, even without previous evidence of DM. 1 Before 2001, SIH in critically ill patients was generally accepted as physiologic. 70 In the aftermath of the Leuven trials, the concept of tight glucose control was enthusiastically incorporated into guidelines including the Surviving Sepsis Campaign 2004 88 and 2008, 89 and those of the ADA 90 and the AACE. 91 Subsequent trials only partially supported these findings or even failed to show a difference with regard to mortality, revealing high incidences of severe hypoglycaemic events as the most harmful complication. 64 73 92 -101 While hyperglycaemia must be avoided, an optimal glucose range for critically ill patients is a topic of ongoing discussion. One trial reported the highest survival rates in ICU patients with glucose levels between 6.2 and 8 mM (111-144 mg dl 21 ), Table 8 Guidelines for glucose management in ambulatory patients 58 Educate patients about signs and symptoms of potential hypoglycaemia and means to treat (15 g of oral dextrose to raise BG by 2.1 mM or 38 mg dl 21 over 20 min). Best to use dextrose or sucrose tablets 126 Follow routine antidiabetic (oral agents or insulin) guidelines for day of surgery Check blood glucose on admission, before surgery, and before discharge at a minimum Point-of-care monitoring is sufficient for stable patients; higher threshold values for hypoglycaemia (e.g. ,3.9 mM or 70 mg dl
21
) and more frequent monitoring may be indicated to ensure patient safety Provide educational material about restarting diet, oral antidiabetic agents, and insulin after discharge Avoid overlap between pre-, intra-, and postoperative insulin
Resumption of preoperative antidiabetic regime should be based on perioperative course and is dependent on oral intake
). 102 Updated guidelines have reached a compromise and generally recommend a BG target of 7.7-10 mM (140 -180 mg dl 21 ) for inpatients as long as these levels can be safely achieved. 79 80 103 -105 Glucose targets and hyperglycaemia Available studies on glucose targets in critically ill patients are difficult to interpret because of substantial differences in study populations and patient management at various centres. Table 9 covers recommended glucose targets issued by diverse societies including adaptations for subgroups at particular risk, covering cardiac surgery, trauma, and neurological patients. The rationale of the Society of Critical Care Medicine's practical guideline to start insulin infusion therapy at 8.3 mM (150 mg dl 21 ) is rooted in their meta-analysis indicating a small, but significant, reduction in the odds ratio for hospital mortality without affecting ICU mortality. 105 Higher trigger values and BG excursions .10 mM (180 mg dl
) are associated with immunosuppressive effects and the potential to exceed the renal threshold for glucosuria. 105 Other societies' guidelines propose a more relaxed BG trigger value of 10 mM (180 mg dl
) to initiate insulin infusion, 29 96 as there is no evidence that targets between 7.7 and 10 mM (140-180 mg dl
) differ from the lower target values of 6.1-7.7 mM (110-140 mg ), as hypoglycaemia increases the risk of focal neurological deficits, encephalopathy, seizures, and permanent cognitive dysfunction in brain-injured patients. 105 Further clinical trials are necessary to define the optimal BG range in this patient population, as case reports of neuroglycopaenia and cerebral distress during insulin infusion, independent of peripheral hypoglycaemia, leave the pathophysiological importance of the rate of glucose change compared with the hypoglycaemic incident unclear.
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In the case of BG levels ,3. 105 113 or when preparing the stabilized patient for transition to the ward. Such an approach must be individualized and might be influenced by hospital or unit policy (Table 10 ).
Glucose monitoring
Critically ill patients can also suffer from hypoglycaemia in the absence of insulin treatment due to concomitant illness such as liver disease, immune compromise, and renal failure.
Patients are also at risk for hypoglycaemia after interruption of caloric intake, with the use of vasoactive infusions, or with renal replacement therapy using bicarbonate-based replacement fluid in sepsis. 114 Arterial or venous whole blood sampling is recommended for BG analysis whenever available and particularly in patients suffering from shock, receiving vasopressor therapy, those with severe peripheral oedema, and those receiving prolonged insulin infusion. 105 The Surviving Sepsis Campaign 103 and Jacobi and colleagues 105 propose a consensus recommendation based on limited data where BG is monitored every 1-2 h during insulin infusion. Protocols that propose checking glucose every 4 h bear a .10% risk of unrecognized hypoglycaemia. 70 94 Transition to ward or IMCU Before discharge to the ward, the majority of stable ICU patients should be transitioned to a protocol-driven basal/ bolus insulin regimen. This can be instituted before the insulin infusion is discontinued to avoid marked swings in BG. 105 (Table 10) . 115 -121 Supplementary correction insulin (in the form of a sliding scale) is titrated according to long-acting insulin and basal -bolus orders. The routine sole administration of sliding-scale insulin to control BG on the ward, IMCU, or ICU is strongly discouraged because of increased GV, incidence of hypo-and hyperglycaemia, 122 and complications during hospitalization. 29 111 123 Ward There is no clear evidence for specific BG goals in non-critically ill postoperative patients. 29 Patients treated with insulin should aim at a pre-meal BG ,7.8 mM (140 mg dl
21
) with random BG values ,10 mM (180 mg dl 21 ), assuming that these targets can be safely achieved. 29 123 More stringent targets can be suggested in stable patients with previous tight glycaemic control. 29 Less stringent values might be appropriate in patients with severe co-morbidities. 29 Hence, for patients with terminal illness, limited life expectancy, or a high risk of hypoglycaemia, a higher BG target .11.1 mM (200 mg dl
) might be reasonable. 123 The definition of hypoglycaemia does not differ based on patient acuity or physical location. Hypoglycaemia is recognized as a BG ,3.9 mM (70 mg dl
), which correlates with the threshold for the release of counter-regulatory hormones, and severe hypoglycaemia is defined as levels ,2.2 mM (40 mg dl 21 ). 29 Outside of the operating theatre and ICU, subcutaneous insulin is recommended and generally accepted as the standard method of insulin administration. 123 There is no study that evaluates IIT in patients on the general ward. Scheduled subcutaneous insulin should involve basal, nutritional, and correction components (with the latter two provided before meals) and should be accompanied by meals with a consistent amount of carbohydrate. 123 Barriers to administering oral hypoglycaemic agents in postoperative inpatients include variability in caloric intake, ileus, and limited ability to titrate the drugs. Metformin, in 112 124 Patients whose glycaemic status was well controlled before hospital admission, however, can usually transition to oral agents 1 or 2 days before discharge. 29 111 Patients on home insulin regimes should ideally resume their preadmission schedule at least 1 day before discharge. 123 
Conclusion
Perioperative dysglycaemia in the adult surgical population is ubiquitous, and unfortunately often undiagnosed. The preponderance of evidence indicates that abnormal glucose homeostasis has an adverse effect on patient outcomes. Anaesthesiologists, as leaders of the 'surgical home' model, are perfectly poised to aid in the identification of these patients, initiate treatment, and facilitate referrals for postoperative care. Given the heterogeneous nature of this population, it is unlikely that one standard of perioperative glycaemic control is appropriate for all patients. Certainly, early identification coupled with timely intervention contributes to significant risk reduction. Although not clearly delineated, the desired level of intraoperative and postoperative glucose control rests somewhere between strict control and overt hyperglycaemia; the goal being adequate control and avoidance of hypoglycaemia. Future investigations will help identify specific perioperative glucose targets, especially in specialized surgical populations (i.e. cardiac, neurosurgical), while advances in monitoring and medications will make it easier to achieve specific glucose targets in individual patients. Closed-loop, continuous monitoring, and management systems with smart alarms and clinical interfaces to enhance glycaemic control are likely to be forthcoming, but are currently not clinically available.
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